Pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma is the commonest cancer of the pancreas, accounting for the large majority of pancreatic tumours. It has a reputation for being untreatable, and that reputation is only partly deserved: for the subset of patients whose tumour can be removed completely, surgery combined with chemotherapy offers a real prospect of long-term survival. The difficulty is that most tumours have spread beyond the point of resectability by the time they cause symptoms.
How it forms
The pancreas has two functions carried out by different tissues: the exocrine tissue, which produces digestive enzymes delivered through a duct system into the duodenum, and the endocrine tissue, which produces insulin and other hormones. Ductal adenocarcinoma arises from the cells lining the exocrine duct system.
The process is gradual. Normal duct cells acquire mutations — characteristically in KRAS first, then in CDKN2A, TP53 and SMAD4 — and pass through recognised precursor stages known as pancreatic intraepithelial neoplasia (PanIN), progressing from mild to severe abnormality before becoming invasive cancer. This progression takes years, which in principle offers a window for earlier detection, though no screening test suitable for the general population yet exists.
Two features of the tumour explain much of its behaviour. First, it provokes a dense fibrous reaction around itself — the desmoplastic stroma — which forms a poorly vascularised barrier that limits the delivery of chemotherapy. Second, it has a strong tendency to spread along nerves (perineural invasion) and into the lymphatics early, which is why a tumour that appears small on a scan may already have spread microscopically.
Recognised risk factors include smoking, which is the strongest modifiable one; long-standing chronic pancreatitis; type 2 diabetes, particularly new-onset diabetes in an older patient without obvious cause; obesity; and a family history. A minority arise in the context of inherited syndromes — BRCA1 and BRCA2, Lynch syndrome, Peutz–Jeghers and hereditary pancreatitis among them — and this matters because it affects both treatment choice and screening of relatives.
Symptoms
Symptoms depend on where in the pancreas the tumour sits. Tumours in the head obstruct the bile duct and therefore declare themselves earlier; tumours in the body and tail grow silently for longer, which is why they present later and are less often resectable.
- Painless jaundice — yellowing of the eyes and skin, dark urine, pale stools and itching. Jaundice without pain in an older patient is a red flag requiring prompt investigation.
- Upper abdominal pain, often dull and boring through to the back, characteristically worse lying flat and eased by sitting forward.
- Unexplained weight loss and loss of appetite.
- New-onset diabetes, or sudden deterioration in established diabetes.
- Steatorrhoea — pale, greasy, offensive stools that are difficult to flush, from failure of enzyme delivery.
- Nausea and vomiting if the duodenum is obstructed.
How the diagnosis is made
Pancreatic protocol CT — a contrast-enhanced scan with arterial and portal venous phases timed specifically for the pancreas — is the central investigation. It defines the tumour and, crucially, its relationship to the major vessels: the superior mesenteric artery, coeliac axis, hepatic artery, superior mesenteric vein and portal vein. That relationship determines resectability.
Endoscopic ultrasound allows detailed imaging and tissue sampling by fine-needle aspiration or biopsy. MRI with MRCP clarifies the ducts and characterises liver lesions. PET-CT is used selectively to detect distant disease.
CA 19-9 is the standard tumour marker. It is useful for monitoring response and detecting recurrence, but it is neither sensitive nor specific enough to diagnose or exclude cancer on its own — it rises in biliary obstruction of any cause, and around 5–10% of people cannot produce it at all.
Staging divides disease into four practical categories, and the category determines the pathway:
- Resectable — no contact with the major arteries and no or minimal venous involvement.
- Borderline resectable — limited contact with vessels that may still permit removal, usually after chemotherapy first.
- Locally advanced — extensive arterial encasement, not removable at presentation.
- Metastatic — spread to liver, peritoneum, lung or elsewhere.
These categories are defined by published criteria, but their application is individualised. The same scan can be read differently by teams with different surgical capability, particularly regarding venous resection and reconstruction, and this is one of the commonest reasons a second opinion changes the plan.
Treatment
Surgery
Complete resection with clear margins is the only route to cure. The operation depends on the site of the tumour:
- Pancreaticoduodenectomy (Whipple procedure) for tumours of the head and uncinate process. The head of the pancreas, duodenum, gallbladder, bile duct and part of the stomach are removed, and the pancreas, bile duct and stomach are reconnected to the small bowel. A pylorus-preserving variant retains the stomach outlet.
- Distal pancreatectomy with splenectomy for tumours of the body and tail.
- Total pancreatectomy where the whole gland is involved, with the consequence of permanent diabetes and lifelong enzyme replacement.
- Venous resection and reconstruction where the tumour involves the portal or superior mesenteric vein. This is standard practice in specialist units and does not by itself make a tumour inoperable. Arterial resection is undertaken far more selectively.
These are major operations, and outcomes are demonstrably better in centres performing them regularly. Minimally invasive and robotic approaches are used in appropriate cases, the decision depending on tumour position and vascular involvement rather than on preference.
Chemotherapy
Chemotherapy is part of treatment for essentially every patient with this diagnosis. Given after surgery it substantially improves survival compared with surgery alone. For borderline resectable disease it is increasingly given first, to treat micrometastatic disease early, to shrink the tumour away from vessels, and to reveal the tumour's biology — disease that progresses during chemotherapy would not have been cured by an operation. Modern combination regimens are more effective than older single agents, and choice depends on fitness and molecular profile.
Radiotherapy
Used selectively, mainly in locally advanced disease or where margins are a particular concern.
Relieving symptoms
Where cure is not possible, a great deal can still be done. Jaundice is relieved by endoscopic stenting of the bile duct. Duodenal obstruction is treated by stenting or bypass. Pain that is difficult to control may respond to coeliac plexus block. Pancreatic enzyme replacement corrects malabsorption and is consistently under-prescribed — many patients lose weight unnecessarily because nobody started it. Nutritional support and early palliative care involvement improve both quality of life and, in some studies, survival.
Recovery after resection
A Whipple procedure typically means eight to fourteen days in hospital and two to three months to full recovery. Distal pancreatectomy is less demanding, often five to eight days. Recognised complications include pancreatic fistula, delayed gastric emptying and bleeding; these are the reason such surgery belongs in units equipped to recognise and manage them.
Afterwards, most patients need pancreatic enzyme replacement with meals. Diabetes may develop or worsen. Appetite and weight take months to recover, and dietetic input is part of proper care rather than an optional extra.
Follow-up
Clinical review, CA 19-9 and CT at regular intervals, most frequently in the first two to three years. Enzyme replacement, diabetic control and nutrition are reviewed at each visit alongside the oncological assessment.
When to seek a specialist opinion
Immediately, and from a high-volume pancreatic unit. Painless jaundice, unexplained weight loss with upper abdominal or back pain, or new diabetes in an older patient without an obvious explanation all warrant prompt investigation rather than watchful waiting.
A second opinion is specifically worthwhile when a tumour has been called inoperable on the basis of vessel involvement, since venous resection is routine in specialist practice and chemotherapy first converts a meaningful proportion of borderline cases to resectable.
Common questions
Why was my jaundice painless?
Because a tumour in the head of the pancreas blocks the bile duct gradually rather than suddenly, unlike a stone, which causes pain as it obstructs. Painless yellowing of the eyes and skin, with dark urine and pale stools, is the presentation that most often leads to an early diagnosis, and it should always be investigated promptly rather than watched.
Can pancreatic cancer be cured?
Yes, in patients whose tumour can be completely removed and who complete chemotherapy. That group is a minority, but it is a real one, and outcomes in it have improved with modern chemotherapy regimens. The critical question is whether the tumour is removable, and that judgement should be made by a specialist pancreatic team.
I have been told it is inoperable. Should I get a second opinion?
It is often worth doing. Involvement of the veins behind the pancreas was once considered a bar to surgery, but resecting and reconstructing those veins is now routine in specialist units. Chemotherapy given first also converts a meaningful proportion of borderline cases into operable ones. A tumour called inoperable because of vessel involvement specifically warrants review by a high-volume pancreatic centre.
What does the Whipple operation involve?
Removal of the head of the pancreas together with the duodenum, the gallbladder, the lower bile duct and sometimes part of the stomach, followed by reconnecting the remaining pancreas, bile duct and stomach to the small bowel. It is a major operation, typically meaning one to two weeks in hospital and two to three months to recover, and results are substantially better in units that perform it regularly.
Why is chemotherapy sometimes given before surgery?
Because it treats cells that may already have spread but cannot yet be seen, shrinks the tumour away from blood vessels to make complete removal more likely, and shows how the disease behaves. It also ensures the treatment is actually received — a proportion of patients never recover sufficiently after surgery to have chemotherapy afterwards.
Why do I need enzyme capsules with meals?
Because the pancreas produces the enzymes that digest fat and protein, and when it is obstructed or partly removed those enzymes are lacking. Without replacement you lose weight, have pale, greasy, floating stools and become deficient in fat-soluble vitamins. The capsules are taken with every meal and snack, and the dose is often too low rather than too high — if symptoms persist, the dose usually needs increasing.
Will I become diabetic?
It is possible, depending on how much pancreas is removed and how much was already damaged. After removal of the whole pancreas it is certain and requires careful insulin management, which is different from ordinary diabetes because the hormone that raises blood sugar is lost too. This is planned for in advance with a specialist diabetes team.
Does it run in families?
Most cases do not, but around one in ten is associated with an inherited genetic change. Genetic testing is worth discussing where there is a family history of pancreatic, breast, ovarian or bowel cancer, or a personal history of melanoma, because it has implications for relatives and occasionally for treatment.
Related conditions
Other conditions of the pancreas covered on this site:
- Acute pancreatitis
- Chronic pancreatitis and its complications
- Pancreatic cysts — IPMN and MCN
- Pancreatic neuroendocrine tumours
- Solid pseudopapillary neoplasm and other rare pancreatic tumours
- Periampullary lesions
- Pancreas divisum
- Annular pancreas
This page provides general information and does not replace an individual medical consultation. Assessment and treatment are decided for each patient after review of their history, examination and imaging, and in the setting of a multidisciplinary team.